Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a developer of immunotherapies for cancer treatment, has appointed Dr Nermeen Varawalla as chief medical officer, effective immediately.
Varawalla brings over 25 years of experience in global pharmaceutical companies, healthcare consultancy, and clinical trial services.
Her expertise includes clinical trial planning and medical affairs, with a strong history of executing global drug development programs, particularly in oncology.
She has built high-performing teams in both Europe and the US and has successfully advanced clinical assets to regulatory and commercial stages at companies like Atlantic Healthcare, BTG (LSE:BTG), and Relief Therapeutics (OTCQB:RLFTF).
"I am delighted to welcome Nermeen to head the very successful clinical team at Scancell," said CEO, Professor Lindy Durrant.
"Her wealth of global sector experience and successful execution of commercial strategies across multiple therapeutic areas but importantly in oncology will be invaluable as we plan ahead for the phase II/III registration study following completion of the SCOPE study.
"The SCOPE study has already delivered excellent results and Nermeen's expertise and input will build on our current capabilities in order to plan and deliver successful future registrational studies."